Design and evaluation of dihydroisoquinolines as potent and orally bioavailable human cytomegalovirus inhibitors.
Following the identification of first pass metabolism issues with our recently described anti-HCMV compounds, the naphthyridines and isoquinolines, we have designed a class of novel metabolically stable and orally bioavailable anti-HCMV agents, the dihydroisoquinolines.
Chan
L
L
BioChem Pharma Inc., Laval, Québec, Canada. chanl@biochempharma.com
Stefanac
T
T
Turcotte
N
N
Hu
Z
Z
Chen
Y
Y
Bédard
J
J
May
S
S
Jin
H
H
D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D001682:Biological Availability; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003587:Cytomegalovirus / Q000187:drug effects*; D015195:Drug Design; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D051379:Mice; D015394:Molecular Structure; D009287:Naphthyridines / Q000737:chemistry; D010627:Phenethylamines / Q000737:chemistry; D010948:Viral Plaque Assay
D000998:Antiviral Agents; D007546:Isoquinolines; D009287:Naphthyridines; D010627:Phenethylamines